pacific biosciences of calif
(PACB:NASDAQ GS)
pacific biosciences of calif (PACB) Snapshot
|
Open
$2.78
|
Previous Close
$2.80
|
|
|
Day High
$2.85
|
Day Low
$2.77
|
|
|
52 Week High
01/17/13 - $3.25
|
52 Week Low
11/15/12 - $1.06
|
|
|
Market Cap
169.7M
|
Average Volume 10 Days
677.8K
|
|
|
EPS TTM
$-1.57
|
Shares Outstanding
60.8M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
pacific biosciences of calif (PACB) Related Businessweek News
No Related Businessweek News Foundpacific biosciences of calif (PACB) Details
Pacific Biosciences of California, Inc. develops, manufactures, and markets an integrated platform for genetic analysis. The company engages in developing a single molecule, real-time, (SMRT) technology for the detection of biological processes. Its SMRT technology enables to study the synthesis, composition, structure, and regulation of DNA, as well as to record individual biochemical events as they occur. It primarily focuses on the deoxyribonucleic acid sequencing market. The company’s product includes the PacBio RS high resolution genetic analyzer, an instrument that conducts, monitors, and analyzes single molecule biochemical reactions in real time. Its PacBio RS high resolution genetic analyzer consists of an instrument platform that uses its proprietary consumables, such as SMRT Cells and reagent kits to prepare and sequence DNA samples. The company’s customers include genome centers, genomics service providers, and agricultural companies, as well as clinical, government, and academic institutions. Pacific Biosciences of California, Inc. markets its products through a direct sales force in North America and Europe, as well as through distributors in Asia. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
pacific biosciences of calif (PACB) Top Compensated Officers
pacific biosciences of calif (PACB) Key Developments
Pacific Biosciences of California, Inc. and Sage Science announced a co-marketing partnership to provide customers of the PacBio RS II the ability to sequence even longer DNA fragments when performing Single Molecule, Real-Time (SMRT(R)) Sequencing.
Pacific Biosciences of California, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported total revenue of $5,578,000 against $10,038,000 a year ago. Operating loss was $20,607,000 against $27,510,000 a year ago. Net loss was $21,104,000 against $27,580,000 a year ago. Basic and diluted net loss per share was $0.37 against $0.50 a year ago. Net cash used in operating activities was $17,575,000 against $17,338,000 a year ago. Purchase of property and equipment was $297,000 against $274,000 a year ago.
Pacific Biosciences of California, Inc., Q1 2013 Earnings Call, Apr 23, 2013
| Recently Viewed | |||
| PACB:US | $2.79 USD | -0.01 |  |
| Company | Last | Change |
| Illumina Inc | $70.40 USD | -1.29 |
| IntelliCell BioSciences Inc | $0.02 USD | -0.0034 |
| Life Technologies Corp | $74.21 USD | -0.06 |
| View Industry Companies | ||
Industry Analysis
PACB
Industry Average
| Valuation | PACB | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 7.5x |
|
| Price/Book | 1.6x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 2.7x |
|
Post a JobJobs
- Chicago, IL | DunnhumbyusaPosted: Jun 18
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
Sponsored Financial Commentaries
Sponsored Links
To contact PACIFIC BIOSCIENCES OF CALIF, please visit www.pacificbiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
